(CR)
(CR)
(D)
(D)DROPOUT
(D)WITHDRAWAL
(D)WITHDRAWAL
(D)WITHDRAWAL
ABBREVIATION
BLOOD PRESSURE ABBREVIATION
BLOOD PRESSURE
BLOOD PRESSURE
BLOOD PRESSURE
BLOOD PRESSURE
BLOOD PRESSURE
BLOOD PRESSURE
BLOOD PRESSURE
BLOOD PRESSURE
BLOOD PRESSURE
BP MEASUREMENT
COMPOSITE COMPARISON
CONSIDERATION
DIASTOLIC BLOOD PRESSURE
DIASTOLIC BLOOD PRESSURE
GROUND RULE
HYDROCHLOROTHIAZIDE
HCTZ PERIOD
HARMONIZATION
HARMONIZATION (ICH)-E9 GUIDELINE
INTERNATIONAL CONFERENCE ON HARMONIZATION
ICH-E9 GUIDELINE
INTENT TO TREAT
INTENT TO TREAT
INTENT TO TREAT
INTENT TO TREAT
INTENT TO TREAT
ITT PRINCIPLE
ITT PRINCIPLE
IMPUTATION METHOD
INTRODUCTION
KAPLAN-MEIER
LAST OBSERVATION CARRIED FORWARD
LAST OBSERVATION CARRIED FORWARD
LAST OBSERVATION CARRIED FORWARD
LAST OBSERVATION CARRIED FORWARD
LAST OBSERVATION CARRIED FORWARD
LAST OBSERVATION CARRIED FORWARD
LAST OBSERVATION CARRIED FORWARD
LAST OBSERVATION CARRIED FORWARD
SECONDARY ANALYSIS LAST OBSERVATION CARRIED FORWARD
LOCF LAST-OBSERVATION-CARRIED-FORWARD
LOCF METHOD
LOCF METHOD
LISTED REASON
MISSING COMPLETELY         AT RANDOM
MISSING COMPLETELY         AT RANDOM
MISSING COMPLETELY         AT RANDOM
MISSING COMPLETELY         AT RANDOM
MISSING COMPLETELY         AT RANDOM
MISSING COMPLETELY         AT RANDOM
MISSING COMPLETELY         AT RANDOM
MCAR CONDITION
MANN-WHITNEY TEST
MEDICAL INVESTIGATOR
MISSING DATA
NEW YORK HEART ASSOCIATION CLASS IV
NEXT
PROPER MULTIPLE IMPUTATION
PROPER MULTIPLE IMPUTATION
PROPER MULTIPLE IMPUTATION
PMI METHOD
POSSIBLE REASON
PREVENTION STUDY
PROPER MULTIPLE IMPUTATION
REGARDING QUESTION
SENSITIVITY ANALYSIS
SENSITIVITY ANALYSIS
TABLE 2I
TREATING NON-CARDIOVASCULAR DEATH
USING PROPORTION
WILCOXON SIGNED-RANK TEST
ACHIEVING COMPARABILITY
ADVICE
ALL-CAUSE MORTALITY
ANALYTICAL STUDY
ASSIGNED TREATMENT
ATHEROGENIC DYSLIPIDEMIA
ATORVASTATIN
BASELINE COVARIATE
BEING MISLED
BEING POST-HOC
CALCULATION
CALCULATION
CANCER HISTORY
CANDESARTAN CILTEXETIL
CARDIOVASCULAR DEATH
CARDIOVASCULAR DEATH
CARDIOVASCULAR EVENT
CHRONIC HEART FAILURE
CLINICAL PRACTICE
CLINICAL STATUS
CLINICAL STATUS
CLINICAL STATUS
CLINICAL STUDY
CLINICAL TRIAL PRACTITIONER
CLINICAL TRIAL PRACTITIONER
CLINICAL TRIAL
CLINICAL TRIAL
CLINICAL TRIAL
CLINICAL TRIAL
CLINICAL TRIAL
CLINICAL TRIAL
COLLABORATION
COMMERCIAL COMPUTER SOFTWARE
COMPLETER
COMPLETER
COMPLETER
COMPLETER
COMPUTER PROGRAM
CONSIDERATION
CONSIDERATION
CONSIDERATION
CONSIDERATION
CONTINUOUS DATA
CONVENTIONAL LAST-OBSERVATION-CARRIED-FORWARD
CORONARY VASODILATORY
COUNTING DEATH
CR
CR
CR
CR
CR
CR
CR
CR
DENOMINATOR
DENOMINATOR
DENOMINATOR
DIABETES TRIAL
DIASTOLIC BLOOD PRESSURE
DIASTOLIC BLOOD PRESSURE
DISTRIBUTION
DOUBLE-BLIND
DOUBLE-BLIND
DOUBLE-BLIND
DOUBLE-BLIND STUDY
DROPOUT CATEGORY
DROPOUT PATTERN
DROPOUT PATTERN
DROPOUT PROBLEM
DROPOUT PROBLEM
DROPOUT PROCESS
DROPOUT PROCESS
DRUG REGISTRATION
EG
EIGHT-WEEK DOUBLE-BLIND PERIOD
ENALAPRIL
END TIME-POINT
END-OF-OBSERVATION
ENDPOINT END-OF-OBSERVATION
CARDIOVASCULAR DEATH ENDPOINT END-OF-OBSERVATION
ENDPOINT
ENDPOINT
ENDPOINT
ENDPOINT
ENDPOINT
ESSENTIAL HYPERTENSION
EXAMINATION
EXERCISE CAPACITY
EXERCISE TEST
EXERCISE TEST
EXERCISE TEST
EXERCISE TEST
EXERCISE TESTING
EXERCISE TESTING
EXERCISE TIME
EXERCISE TIME
EXERCISE TIME
EXERCISE TIME VALUE
EXPLANATORY TRIAL
FINAL VISIT
FLAW
FOLLOW-UP DATA
FOLLOW-UP DATA
FORCED DROPOUT
FOUR-WEEK
GROUPS TRIAL
HAVING VALUE
HEMODYNAMIC MEASURE
HEMODYNAMIC
HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE
IE
IE
ILLUSTRATION
ILLUSTRATION
ILLUSTRATION
IMPUTATION METHOD
IMPUTATION METHOD
IMPUTATION METHOD
INCOMPARABILITY
INDIVIDUAL CASE
INFORMATIVE MISSING DATA
INVESTIGATION
INVESTIGATOR
LIFE DATA
LIPOPROTEIN LEVEL
LIPOPROTEIN SUBFRACTION
LONGITUDINAL DATA
LONGITUDINAL STUDY CASE
LOSS-TO-FOLLOW-UP
LOVASTATIN
MEASUREMENT VALUE
MEASUREMENT
MEDICAL INVESTIGATOR
MEDICAL JOURNAL ARTICLE
MEDICAL PROCEDURE
MEDICAL PUBLISHING INDUSTRY
MEDICAL VISIT
MIRROR IMAGE
DROPOUT PROBLEM MIRROR IMAGE
MISCONCEPTION
MISSING DATA
MISSING DATA
MISSING DATA
MISSING DATA
MISSING DATA
MISSING DATA
MISSING DATA
MISSING DATA
MISSING DATA
MISSING DATA SET
MISSING EXERCISE TIME DATA
MISSING VALUE
MMHG DECREASE
MULTICENTER
MULTICENTER
MULTICENTER
NEGATIVE STUDY
NIACIN
NIFEDIPINE-GIT
NON-PARAMETRIC
NON-PARAMETRIC METHOD
NON-PARAMETRIC METHOD
NUISANCE EFFECT
NUMERATOR
OBJECTIVE
OBJECTIVE
OBSERVATIONAL STUDY
OBSERVATIONAL STUDY
OBSERVATION
OBSERVATION
OBSERVATION
OMAPATRILAT
OPEN-LABEL
ORIGINAL MEASUREMENT UNIT
OUTCOME MEASURE
OUTCOME-CORRELATED BASELINE CHARACTERISTIC
OVER-CORRECTION
PARAMETRIC
PARAMETRIC CASE
PARTICIPANT
PHARMACOLOGICAL PROPERTY
PIMOBENDAN
POPULAR APPROACH
POPULAR PRACTICE
POSITIVE STUDY
POST-RANDOMIZATION STRATIFICATION
POST-THERAPY OBSERVATION
POTENTIAL BIAS
POTENTIAL USEFULNESS
PRACTICAL QUESTION
PRACTICAL USAGE
PRACTITIONER
PRAGMATIC TRIAL
PRE-SPECIFIED MODEL
PRIMARY ENDPOINT
PRIMARY PRE-SPECIFIED ANALYSIS
EXERCISE TIME PRIMARY PRE-SPECIFIED ANALYSIS
PRIMARY RESPONSE VARIABLE
PROTOCOL VIOLATION
QUESTION MARK
RANDOMIZATION MECHANISM
RANDOMIZED PATIENT
RANDOMIZED PATIENT
RANDOMIZED SUBJECT
RANDOMIZED SUBJECT
RANDOMIZED TRIAL
REGRESSION MODEL
REGRESSION MODEL
REGRESSION MODEL
RELATIVE COMPARISON
TREATMENT EFFECT RELATIVE COMPARISON
RESEARCH TOPIC
RESPONDER
RESPONDER
RESPONDER
RESTRICTIVE ASSUMPTION
RESTRICTIVE MODEL
REVIEW ATTEMPT
SECONDARY ANALYSIS
SEMI-OBSERVATIONAL STUDY IMBEDDED
SENSITIVITY ANALYSIS
SIDE EFFECT
SIDE EFFECT
SIDE EFFECT
SIDE EFFECT
SIDE EFFECT
SIDE EFFECT
SIDE EFFECT
SIDE EFFECT
SIDE EFFECT
SIMULATION RESULT
SIX-MONTH
STATISTICAL ANALYSIS
STATISTICAL CONCEPT
STATISTICAL LITERATURE
STATISTICAL MODEL
STATISTICAL TERM
STATISTICAL TEST
STATISTICAL TOOL
STUDY CONCLUSION
STUDY MEDICATION
STUDY PROCEDURE
STUDY SAMPLE
STUDY THERAPY
STUDY THERAPY
STUDY TREATMENT
SUBGROUP
SUBGROUP
SUBGROUP
SUBJECT
SUBJECT
SUBJECT
SUBJECT
SURVEY RESEARCH
SURVIVAL ANALYSIS
SURVIVAL TECHNIQUE
SURVIVAL TIME
SYSTOLIC BLOOD PRESSURE
TECHNICAL REVIEW
TERMINAL DISEASE PROGRESSION STAGE
TESTING PROCEDURE
TIME-POINT
TIME-TO-EVENT DATA
TITRATION STUDY
OMAPATRILAT TITRATION STUDY
TREATMENT CODE
TREATMENT EFFECT
TREATMENT EFFECT
TREATMENT EFFECT
TREATMENT EFFECT
TREATMENT EFFECT
NIACIN TREATMENT EFFECT
PIMOBENDAN TREATMENT EFFECT
TREATMENT EFFECT
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT GROUP
TREATMENT PERIOD
TRIAL MONITORING
TRIAL PROCEDURE
VENTRICULAR MASS
VERAPAMIL-SR
VISIT TIME-POINT
WITHDRAWAL
WITHDRAWAL
WITHDRAWAL
WITHDRAWAL
WITHDRAWAL
WITHDRAWAL
WITHDRAWAL
WITHDRAWAL
WITHDRAWAL
WITHDRAWAL
WITHDRAWAL
WITHIN-SUBJECT VARIABILITY
WORSE RANK
BLOOD PRESSURE
BP
HCTZ
DBP
INTENT TO TREAT
ITT
MISSING COMPLETELY         AT RANDOM
MCAR
INTERNATIONAL CONFERENCE ON HARMONIZATION
ICH
LAST-OBSERVATION-CARRIED-FORWARD
LOCF
PMI
MISSING AT RANDOM
MAR
PARTIAL IMPUTATION
PI
MEASUREMENT
GROUND
HARMONIZATION
(ICH)-E9 GUIDELINE
guidelines
principles
principles
IMPUTATION
tests
PREVENTION
multiple imputation
questions
analyses
analyses
TABLE
NON-CARDIOVASCULAR DEATH
SIGNED-RANK TEST
comparability
MORTALITY
studies
treatments
DYSLIPIDEMIA
baseline
histories
CILTEXETIL
deaths
deaths
heart failure
practices
studies
CLINICAL TRIAL
CLINICAL TRIAL
COMPUTER
VASODILATORY
BLOOD PRESSURE
BLOOD PRESSURE
studies
dropouts
dropouts
dropouts
dropouts
problems
dropouts
problems
dropouts
dropouts
drugs
ends
EXERCISE
EXERCISE
tests
EXERCISE
tests
EXERCISE
tests
EXERCISE
tests
EXERCISE
EXERCISE
EXERCISE
times
EXERCISE
times
EXERCISE
times
EXERCISE TIME
EXERCISE
visits
FOLLOW-UP
FOLLOW-UP
trials
IMPUTATION
IMPUTATION
IMPUTATION
cases
lives
longitudinal study
MEASUREMENT
MEDICAL JOURNAL
images
decreases
effects
studies
outcomes
measures
OUTCOME-CORRELATED BASELINE
baseline
cases
practices
STRATIFICATION
OBSERVATION
biases
questions
usage
PRE-SPECIFIED
ENDPOINT
PRE-SPECIFIED ANALYSIS
PRE-SPECIFIED
RESPONSE VARIABLE
protocols
questions
MARK
SUBJECT
trials
REGRESSION
REGRESSION
comparisons
RESEARCH
REVIEW
analyses
analyses
SIDE
SIDE
SIDE
SIDE
SIDE
SIDE
SIDE
SIDE
SIDE
simulations
analyses
studies
CONCLUSION
studies
MEDICATION
studies
studies
studies
studies
studies
treatments
surveys
RESEARCH
SURVIVAL
analyses
SURVIVAL
SURVIVAL
times
BLOOD PRESSURE
REVIEW
studies
treatments
treatments
effects
treatments
effects
treatments
effects
treatments
effects
treatments
effects
treatments
treatments
treatments
treatments
treatments
treatments
treatments
treatments
treatments
treatments
treatments
treatments
treatments
trials
trials
visits
